The focus of our work is to understand the pathogenesis and the biology of thyroid cancers with the goal of identifying new molecular-based therapies. Thyroid cancer is the most common endocrine malignancy. Exposure to radiation during childhood confers increased predisposition to this disease. Our lab has been instrumental in characterizing many of the somatic genetic changes associated with thyroid tumor initiation and progression in both radiation-induced and sporadic thyroid cancer, and in defining the functional consequences using in vitro and in vivo experimental models.
James A. Fagin, MD
Research FocusPhysician-scientist James Fagin focuses on the pathogenesis of thyroid cancer and the role of oncogenic kinases.
- MD, University of Buenos Aires School of Medicine (Argentina)
- Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale AJ, Sherman EJ, Ryder M, Ghossein RA, Rosen N, Fagin JA. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas. Cancer Discovery 2013, May;3(5):520-33.
- Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Dominguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. Engl J Med 2013; Feb 14;368(7):623-32.
- President, American Thyroid Association (2012)
- UK Clinical Endocrinology Trust Medal Lecture Award (2011)
- Sydney Ingbar Award, American Thyroid Association (2008)
- Merck Prize, European Thyroid Association Award (2007)
- Association of American Physicians Award (2001)
- American Society of Clinical Investigation Award (1998)